Wockhardt Limited has reported a revenue of INR3,373 crores and an EBITDA of INR630 crores for the current financial year, representing an EBITDA growth of 51%. The company’s profitability before tax stood at INR238 crores, while it holds a cash equivalent of INR662 crores and a net debt-to-equity ratio of 0.1. These results were shared during an investor conference held on June 04, 2026.

The company’s financial performance reflects a strategic shift towards profitability over the last three years, with the EBITDA margin rising from 5.4% to 18.6%. Wockhardt exited its loss-making US generic business to focus on higher-margin segments. The specialty business, comprising biosimilars and novel antibiotics, now contributes 23% of the total business. The biosimilar and biotech business grew by 27%, driven by production improvements in human insulin and Glargine.

Financial and Operational Highlights

Regionally, the emerging market business, which accounts for 28% of turnover, grew by 35%, supported by strategic partnerships in Brazil, Thailand, Algeria, and Malaysia. The UK business, comprising 39% of total operations, grew by 13% with a focus on specialty injectables. The India business is driven by an innovative portfolio including Emrok, Miqnaf, and regenerative medicine.

Strategic Growth Drivers

Wockhardt is entering a new phase of growth centered on its novel antibiotic platform. The company received US FDA approval for Zaynich, making it the first Indian company to have an Indian research product approved by the US FDA. Zaynich is a beta-lactamase enhancer antibiotic designed to treat carbapenem-resistant gram-negative infections. The management plans to launch Zaynich globally, starting with the US and India in the current year, followed by Europe and emerging markets in subsequent years.

The company has onboarded a specialized leadership team for the US market, including experts in commercialization, medical affairs, and market access. The US commercialization strategy will be asset-light, partnering with a commercialization partner for logistics and operational aspects while retaining strategy and execution in-house. The company expects to breakeven on the bottom line for the Zaynich business within 12 to 18 months.

Future Outlook

Looking ahead, Wockhardt aims to accelerate its biotech business, focusing on diabetes biosimilars. The company has registered in 30 emerging markets and has five products in the pipeline, including Aspart, RN 30/70, Degludec, Degludec Aspart, and Semaglutide. The management projects a normal capital expenditure of INR200 crores to INR300 crores over the next three years, primarily for increasing biological capacity.

The company estimates the global peak sales potential for Zaynich to be between $1.5 billion and $2 billion annually. In the US, the daily cost for newer antibiotics is estimated between $1,200 and $1,500, with India prices expected to be discounted by 75% to 80% relative to US pricing. Wockhardt intends to maintain its focus on antibiotic research for the next decade.

Wockhardt Limited reported a financial performance for FY26 with an income of INR 3,373 Cr. and EBITDA of INR 630 Cr., representing a 51% year-over-year growth. The company disclosed these figures during an investor meeting held on June 4, 2026, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presentation highlighted the company's strategic focus on novel antibiotics, pharmaceuticals, and biotechnology, alongside a robust cash position of INR 662 Cr. and a net debt-to-equity ratio of 0.10 as of March 31, 2026.

Key Financials and Operational Performance

The investor presentation provided a detailed breakdown of Wockhardt's operational segments, showing significant regional contributions. The UK business achieved a 13% YoY growth driven by specialty injectables, while Ireland reported a 16% YoY growth in liquids and creams. Emerging Markets saw a 35% YoY growth, supported by strategic partnerships in Brazil, Thailand, Algeria, and Malaysia. The India business recorded an 8% YoY growth, led by an innovative portfolio including Emrok, Miqnaf, and Regenerative products.

Strategic Growth Drivers

Management outlined a strategic roadmap focusing on the Zaynich global business, biotech acceleration, and a differentiated pharma R&D pipeline. A key highlight was the approval of Zaynich by the US FDA and CDSCO (India), positioning the company to address carbapenem-resistant infections. The company aims to enter 7-8 key markets with high CR burden in Latin America, Eurasia, GCC, and South/South East Asia within the next 18-24 months.

Future Outlook

Looking ahead, Wockhardt stated its objectives for the next two years include growth acceleration and sustainable operational excellence enabled by AI. The company emphasized its biosimilar diabetes franchise, with manufacturing infrastructure ready and a focus on human insulin and glargine, targeting a market size of approximately US$ 1.5 Billion. The pipeline includes assets such as Aspart, Degludec, and Semaglutide, targeting a market size of ~ US$ 5.6 Billion.